Accenture Invests in Ocean Genomics to Accelerate AI-driven Drug Discovery and the Development of Personalized Medicines
Retrieved on:
Thursday, February 16, 2023
Other Health, Pharmaceutical, Research, Software, Artificial Intelligence, Start-Up, Networks, Finance, Consulting, Data Management, Professional Services, Science, Technology, General Health, Data Analytics, Biotechnology, Health, Health Technology, Messenger, Therapy, Genomics, NYSE, Drug development, Algorithm, RNA, Breath: The New Science of a Lost Art, Disease, Creativity, Multimedia, Drug discovery, AI, Gene expression, Medical device, Pharmaceutical industry, Accenture
(Graphic: Business Wire)
Key Points:
- (Graphic: Business Wire)
Based in Pittsburgh, Ocean Genomics creates software that provides modeling and an understanding of changes and variants in mRNA to enable a more accurate prediction of a patient’s biological response to a drug. - In collaboration with Ocean Genomics, biopharma companies use the technology in in-silico drug discovery to develop treatments based on an individual's personal biology.
- The global personalized medicine market size is expected to reach more than $796 billion by 2028.
- “As biopharma companies move to increasingly precise and effective therapies, they seek the talent, technology and insights to enable more personalized, data-driven drug discovery,” said Carl Kingsford, Ph.D., co-founder and CEO of Ocean Genomics.